Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from CStone Pharmaceuticals ( (HK:2616) ) is now available.
CStone Pharmaceuticals’ board has granted 15,715,500 share options to 96 grantees and 8,055,000 restricted share units (RSUs) to 88 grantees under its post-IPO equity incentive schemes, with allocations covering one director and multiple employees including senior management, at no consideration and based on recent market prices. Because the combined options and RSUs awarded to director Dr. Jianxin Yang over a 12‑month period exceed 1% of the company’s issued share capital, these grants are subject to shareholder approval at the upcoming annual general meeting, highlighting both an expanded management incentive program and potential dilution that shareholders and investors are being cautioned to consider.
The most recent analyst rating on (HK:2616) stock is a Sell with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
More about CStone Pharmaceuticals
CStone Pharmaceuticals is a Hong Kong–listed biopharmaceutical company focused on developing and commercializing innovative oncology therapies, with its operations and employee incentive structures governed under post-IPO equity schemes in line with Hong Kong Listing Rules.
Average Trading Volume: 9,243,507
Technical Sentiment Signal: Buy
Current Market Cap: HK$7.96B
See more data about 2616 stock on TipRanks’ Stock Analysis page.